Powder: -20°C for 3 years | In solvent: -80°C for 1 year
WNY1613 is a potent and selective PI3Kδ inhibitor with a piperazinone-containing purine scaffold.WNY1613 has anti-NHL effects in vitro and in vivo.WNY1613 inhibits phosphorylation of the downstream component of PI3K in NHL cell lines and induces apoptosis in cancer cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,520.00 | |
50 mg | 8-10 weeks | $ 1,980.00 | |
100 mg | 8-10 weeks | $ 2,500.00 |
Description | WNY1613 is a potent and selective PI3Kδ inhibitor with a piperazinone-containing purine scaffold.WNY1613 has anti-NHL effects in vitro and in vivo.WNY1613 inhibits phosphorylation of the downstream component of PI3K in NHL cell lines and induces apoptosis in cancer cells. |
Molecular Weight | 557.65 |
Formula | C29H35N9O3 |
CAS No. | 2650546-39-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
WNY1613 2650546-39-5 inhibitor inhibit